Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Paclitaxel + Cisplatin in Esophageal/GEJ Adenocarcinoma
NCT00003237Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jun 1998
- Primary completion
- Oct 2003
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma and Gastric Cardia Adenocarcinoma, sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Disease Free Survival and Overall Survival. Started Jun 1998; status: completed.
02
Drugs
paclitaxelcisplatin
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomaGastric Cardia Adenocarcinoma
Beyond the preview
Go deeper on NCT00003237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003237.